QIAGEN N.V. is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of September 30, 2020, QIAGEN employed more than 5,300 people in over 35 locations worldwide. Further information can be found at www.qiagen.com.
- Academic Category : Diagnostic genetics - Product Category : DNA/RNA Based reagents, Genetic Testing - Product Information This kit is a real-time qualitative IVD PCR test for the detection of 11 mutations in the PIK3CA gene. It is the first CDx test approved by the FDA to aid identification of breast cancer patients potentially eligible for treatment with PIQRAY(alpelisib) in combination with the fulvestrant.
- Academic Category : Diagnostic genetics - Product Category : DNA/RNA Based reagents, Genetic Testing, DNA Viral Testing - Product Information This reagent is for concentration and purification of free-circulating DNA and RNA from plasma for in vitro diagnostic use. ccfDNA purified using this Kit is ready for use in a wide range of downstream applications, including NGS, RT-PCR, digital PCR, multiplex PCR and quantitative PCR.